Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $650M senior secured term loan fully drawn on November 2, 2026 to fund the merger, refinance debt, transaction costs, and corporate purposes.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $650M senior secured term loan fully drawn on November 2, 2026 to fund the merger, refinance debt, transaction costs, and corporate purposes
- Initial interest: Term SOFR plus 2.25% or Base Rate plus 1.25%, at the company’s option
- Post-reporting-period pricing: Term SOFR spread 2.00%-2.75%, tied to total net leverage
- First-priority liens on substantially all Loan Party assets, with subsidiary guarantees increasing creditor priority
- Leverage and interest-coverage covenants may constrain acquisitions, dividends, additional debt, and other capital allocation_strategy
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Supernus shareholders converted into Indivior shares at a 1.5401 exchange ratio, completing the merger
- Supernus equity awards rolled into Indivior awards, preserving existing vesting terms for RSUs and options
- Performance-based Supernus PSUs converted to time-based Indivior RSUs, removing performance conditions
- Supernus options now cover Indivior shares, with share counts and exercise prices adjusted for the exchange ratio
- Shareholders receive cash instead of fractional Indivior shares, with merger terms governed by the previously filed agreement
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material financial obligation arose from an agreement disclosed elsewhere in the filing
- Investors should review Item 1.01 for the obligation’s amount, payment terms, maturity and business purpose
Item 3.03 · Material Modification to Rights of Security Holders
- Supernus shareholders’ equity rights terminated at the merger’s effective time
- Each outstanding share converted into the merger consideration described under Item 2.01
- Former shareholders retain only the right to receive merger consideration, with no continuing ownership rights
- Event signals completion of the transaction and elimination of Supernus common stockholder status
Item 5.01 · Changes in Control of Registrant
- Merger effective, triggering a change in control of Supernus Pharmaceuticals
- Certificate of incorporation amended and restated in full at the merger effective time
- Investors should review Item 2.01, Item 3.03 and Item 5.03 for transaction terms, shareholder rights and governance changes
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws fully amended and restated at merger closing
- Charter documents now reflect the surviving corporation structure following the merger
- Changes formalize post-merger governance and corporate framework for shareholders
Item 7.01 · Regulation FD Disclosure
- Supernus announced completion of its merger, making the transaction effective for shareholders
- Combined-company structure may change Supernus’s ownership, financial reporting and strategic direction
- Exhibit 99.1 contains transaction details, including consideration, ownership and expected operating impact
Item EX-99.1 · Exhibit EX-99.1
- Merger completed, creating Supernus, Inc., an 11-product CNS platform spanning opioid use disorder, psychiatry, and neurology
- Former Indivior holders own 56.5% and former Supernus holders 43.5%, materially shifting ownership and governance control
- $1.0 billion special cash dividend funded partly by a $650 million Citibank term loan, increasing combined-company leverage
- Five named growth drivers, including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE, support the expanded commercial strategy
- Combined company trades as SUPN on Nasdaq Global Market beginning November 3, 2026, following legacy Supernus delisting
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.